US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MBX Biosciences

15.53

+0.57003.81%

Volume:458.82K

Turnover:7.07M

Market Cap:519.08M

PE:-3.95

High:15.92

Open:14.97

Low:14.82

Close:14.96

Loading ...

Overview Company News Filings

My Foodie Box Limited Achieves Financial Turnaround and Strategic Partnership

My Foodie Box Pursues Strategic Acquisition for ASX Reinstatement

BUZZ-U.S. STOCKS ON THE MOVE-Commvault Systems, Rockwell Automation, Tesla

MBX Biosciences' Hypoparathyroidism Treatment a 'Key Catalyst,' Oppenheimer Says

MT Newswires Live

BUZZ-U.S. STOCKS ON THE MOVE-Legend Biotech, Unity Software, MP Materials

BUZZ-U.S. STOCKS ON THE MOVE-Johnson & Johnson, Easterly Government Properties, Bank of America

BUZZ-Oppenheimer initiates coverage on MBX Biosciences with 'outperform'

MBX Biosciences initiated with an Outperform at Oppenheimer

Microbix Partners with Bulgaria’s NCIPD to Enhance Diagnostic Test Accuracy

Guggenheim Keeps Their Buy Rating on MBX Biosciences, Inc. (MBX)

Press Release: MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

Strategic Growth and Clinical Advancements Propel MBX Biosciences to a Buy Rating

MBX Biosciences Submits IND Application for MBX 4291, Paving Way for Phase 1 Trial in Q3 2025

MBX Biosciences Inc. Concluded Annual Stockholders Meeting

MBX Biosciences to Participate in June Investor Conferences

Buy Rating for Microbix Biosystems: Strong Antigen Revenue Growth and Mid-Term Market Potential

MBX Biosciences Reports Q1 2025 Financial Progress

MBX Biosciences Q1 EPS $(0.71) Beats $(0.77) Estimate

Press Release: MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Microbix Biosystems to Release Q2 Fiscal 2025 Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MBX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MBX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","market":"US","secType":"STK","nameCN":"MBX Biosciences","latestPrice":15.53,"timestamp":1753901463050,"preClose":14.96,"halted":0,"volume":458824,"delay":0,"floatShares":13610296,"shares":33424371,"eps":-3.929565,"marketStatus":"Trading","change":0.57,"latestTime":"07-30 14:51:29 EDT","open":14.97,"high":15.92,"low":14.815,"amount":7068481.037951999,"amplitude":0.073864,"askPrice":15.62,"askSize":521,"bidPrice":15.44,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-3.929565,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1753905600000},"marketStatusCode":2,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":14.96,"postHourTrading":{"tag":"盘后","latestPrice":14.96,"preClose":14.96,"latestTime":"19:32 EDT","volume":4178,"amount":62502.96,"timestamp":1753831979207},"volumeRatio":0.857165,"impliedVol":2.4042,"impliedVolPercentile":0.7403},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","floatShares":13610296,"roa":"-31.68%","roe":"-48.22%","lyrEps":-5.818121,"volumeRatio":0.857165,"shares":33424371,"dividePrice":0,"high":15.92,"amplitude":0.073864,"preClose":14.96,"low":14.815,"week52Low":4.8069,"pbRate":"2.20","week52High":27.5,"institutionHeld":0,"latestPrice":15.53,"committee":-0.445215,"eps":-3.929565,"divideRate":0,"volume":458824,"delay":0,"ttmEps":-3.929565,"open":14.97,"prevYearClose":18.43,"prevWeekClose":14.57,"prevMonthClose":11.41,"prevQuarterClose":11.41,"fiveDayClose":13.68,"twentyDayClose":11.61,"sixtyDayClose":12},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MBX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2555035837","title":"My Foodie Box Limited Achieves Financial Turnaround and Strategic Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2555035837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555035837?lang=en_us&edition=fundamental","pubTime":"2025-07-29 16:05","pubTimestamp":1753776341,"startTime":"0","endTime":"0","summary":"My Foodie Box Limited ( ($AU:MBX) ) has shared an announcement. My Foodie Box Limited reported a significant financial turnaround for the year endi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/my-foodie-box-limited-achieves-financial-turnaround-and-strategic-partnership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/my-foodie-box-limited-achieves-financial-turnaround-and-strategic-partnership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4023","BOX","LU0012050646.USD","LU0240878834.USD","LU0106261612.USD","LU0240877869.USD","BK4007"],"gpt_icon":0},{"id":"2553208635","title":"My Foodie Box Pursues Strategic Acquisition for ASX Reinstatement","url":"https://stock-news.laohu8.com/highlight/detail?id=2553208635","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553208635?lang=en_us&edition=fundamental","pubTime":"2025-07-24 16:52","pubTimestamp":1753347173,"startTime":"0","endTime":"0","summary":"An update from My Foodie Box Limited ( ($AU:MBX) ) is now available. My Foodie Box Limited has completed the divestment of its meal kit business an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/my-foodie-box-pursues-strategic-acquisition-for-asx-reinstatement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/my-foodie-box-pursues-strategic-acquisition-for-asx-reinstatement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0012050646.USD","BOX","BK4007","LU0240877869.USD","MBX","LU0106261612.USD","BK4023","LU0240878834.USD"],"gpt_icon":0},{"id":"2552249421","title":"BUZZ-U.S. STOCKS ON THE MOVE-Commvault Systems, Rockwell Automation, Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=2552249421","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552249421?lang=en_us&edition=fundamental","pubTime":"2025-07-17 00:21","pubTimestamp":1752682863,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Commvault Systems, Rockwell Automation, TeslaEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nL6N3TD0MQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0006306889.USD","DEA","TSYW.SI","JNJ","LU2112291526.USD","LU1127390331.HKD","MSI","VG","CNX","IE00B19Z8W00.USD","SG9999001440.SGD","EQT","LU0170899867.USD","LU0950375773.USD","NEM","IE00BJTD4V19.USD","GANX","MTDR","KRC","BAC","DVN","AXON","LU0130102774.USD","KLAC","UHS","LU0265550946.USD","EOG","ROK","LU2264538146.SGD","LU0082616367.USD","F","PLD","SG9999014914.USD","MBX","LU1066053197.SGD","TSLA","OVV","NFE","UNFI","CVLT","LU0006061336.USD","CNC","LU1791807156.HKD","AMAT","LEGN","LU1778281490.HKD"],"gpt_icon":1},{"id":"2551129520","title":"MBX Biosciences' Hypoparathyroidism Treatment a 'Key Catalyst,' Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2551129520","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551129520?lang=en_us&edition=fundamental","pubTime":"2025-07-16 22:43","pubTimestamp":1752677015,"startTime":"0","endTime":"0","summary":"MBX Biosciences'  hypoparathyroidism drug, canvuparatide, is a \"key catalyst\" for the company as its potentially favorable efficacy to current treatments could be a $2 billion global peak sales opportunity, said Oppenheimer said in a Wednesday note.Oppenheimer said its enthusiasm for MBX Biosciences stems from the company's precision endocrine peptide platform and its potential to \"redefine standards\" in endocrine and metabolic disease treatment.The firm initiated coverage on MBX Biosciences with an outperform rating and a $38 price target.Price: 12.40, Change: -1.00, Percent Change: -7.46","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MBX","OPY","BK4127","BK4007","BK7040","MBX.AU"],"gpt_icon":0},{"id":"2551234981","title":"BUZZ-U.S. STOCKS ON THE MOVE-Legend Biotech, Unity Software, MP Materials","url":"https://stock-news.laohu8.com/highlight/detail?id=2551234981","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551234981?lang=en_us&edition=fundamental","pubTime":"2025-07-16 21:09","pubTimestamp":1752671354,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Legend Biotech, Unity Software, MP MaterialsEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call n","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nL6N3TD0DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348723411.USD","AMAT","LU2468319806.SGD","01548","KRC","LU0308772762.SGD","LU2746668461.USD","BK1576","JNJ","LU1880398471.USD","EOG","UNFI","BAC","BK4139","LU1670710661.SGD","IE00B19Z3581.USD","LU0889565833.HKD","OVV","U","LU2168564222.USD","KLAC","LU0061474960.USD","MTDR","IE00BFSS8Q28.SGD","LU1066051811.HKD","MBX","LU0211327993.USD","BK4077","DVN","IE00BMPRXR70.SGD","LRCX","LU1718418525.SGD","LU2237443622.USD","LEGN","LU1815333072.USD","CNC","BK4127","LU0130103400.USD","LU0648000940.SGD","DEA","LU1670710588.SGD","GB00B4LPDJ14.GBP","IE0004445015.USD","LU2023250843.SGD","LU1923623000.USD","LU2764263039.SGD","MP","VG"],"gpt_icon":1},{"id":"2551140137","title":"BUZZ-U.S. STOCKS ON THE MOVE-Johnson & Johnson, Easterly Government Properties, Bank of America","url":"https://stock-news.laohu8.com/highlight/detail?id=2551140137","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551140137?lang=en_us&edition=fundamental","pubTime":"2025-07-16 19:54","pubTimestamp":1752666843,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Johnson & Johnson, Easterly Government Properties, Bank of AmericaEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7T","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nL6N3TD0GA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0130517989.USD","LU1642822529.SGD","DEA","LU2089284900.SGD","LU1839511570.USD","MBX","SGXZ99366536.SGD","LU1267930813.SGD","LU0308772762.SGD","LU0203202063.USD","BK4588","IE000M9KFDE8.USD","BAC","EOG","LU1069344957.HKD","LU1201861249.SGD","IE00BN8TJ469.HKD","KRC","AMAT","LU2458330169.SGD","LU2381873111.SGD","LU0476273544.USD","LU1989773731.SGD","LU0820561818.USD","OVV","LU2264538146.SGD","LU1267930730.SGD","IE00BD6J9T35.USD","LU1506573853.SGD","IE0004091025.USD","LU0661504455.SGD","LU1880398554.USD","LU1989763005.USD","LU0077335932.USD","LU0256863902.USD","KLAC","LU0130518102.USD","LU1951200564.SGD","LU0267386448.USD","BK4592","JNJ","LU1435385759.SGD","LU0149725797.USD","LU0256331488.USD","DVN","MTDR","LU1496350171.SGD","LRCX","LU0788109394.HKD"],"gpt_icon":1},{"id":"2551142666","title":"BUZZ-Oppenheimer initiates coverage on MBX Biosciences with 'outperform'","url":"https://stock-news.laohu8.com/highlight/detail?id=2551142666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551142666?lang=en_us&edition=fundamental","pubTime":"2025-07-16 18:38","pubTimestamp":1752662328,"startTime":"0","endTime":"0","summary":"BUZZ-Oppenheimer initiates coverage on MBX Biosciences with 'outperform'** Brokerage Oppenheimer initiates coverage on biotech firm MBX Biosciences MBX.O with PT of $38 and \"outperform\" rating** \"Our enthusiasm stems from the company's innovative Precision Endocrine Peptide  platform and its potential to redefine standards in endocrine and metabolic disease treatment,\" says Oppenheimer** Brokerage sees its mid-stage experimental treatment, canvuparatide, for hypoparathyroidism as a \"key catalyst\" for this quarter     ** New price target represents a 183.6% upside to the stock's last close ** Brokerage believes co's \"lead candidate canvuparatide's once-weekly injections and potentially favorable efficacy to the current daily injectable standard could make it best-in-class—supporting ~$2 billion global peak sales opportunity\"** Brokerage says co's another mid-stage drug, imapextide, which is a long-acting glucagon-like peptide-1  receptor antagonist, could be more than a $1 billion oppor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nL4N3TD0R9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX"],"gpt_icon":0},{"id":"2551144016","title":"MBX Biosciences initiated with an Outperform at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2551144016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551144016?lang=en_us&edition=fundamental","pubTime":"2025-07-16 18:15","pubTimestamp":1752660940,"startTime":"0","endTime":"0","summary":"Oppenheimer initiated coverage of MBX Biosciences (MBX) with an Outperform rating and $38 price target The analyst is positive on potential of the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-initiated-with-an-outperform-at-oppenheimer-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-initiated-with-an-outperform-at-oppenheimer-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","OPY"],"gpt_icon":0},{"id":"2549447245","title":"Microbix Partners with Bulgaria’s NCIPD to Enhance Diagnostic Test Accuracy","url":"https://stock-news.laohu8.com/highlight/detail?id=2549447245","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549447245?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:55","pubTimestamp":1751975749,"startTime":"0","endTime":"0","summary":"The latest update is out from Microbix Biosystms ( ($TSE:MBX) ). Microbix Biosystems Inc. has entered into a multi-year agreement with Bulgaria’s N...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-partners-with-bulgarias-ncipd-to-enhance-diagnostic-test-accuracy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-partners-with-bulgarias-ncipd-to-enhance-diagnostic-test-accuracy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2548894854","title":"Guggenheim Keeps Their Buy Rating on MBX Biosciences, Inc. (MBX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2548894854","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548894854?lang=en_us&edition=fundamental","pubTime":"2025-07-02 19:45","pubTimestamp":1751456743,"startTime":"0","endTime":"0","summary":"Guggenheim analyst maintained a Buy rating on MBX Biosciences, Inc. today and set a price target of $44.00. The company’s shares closed yesterday a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-mbx-biosciences-inc-mbx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-mbx-biosciences-inc-mbx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX"],"gpt_icon":0},{"id":"2545192434","title":"Press Release: MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2545192434","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545192434?lang=en_us&edition=fundamental","pubTime":"2025-06-23 20:00","pubTimestamp":1750680000,"startTime":"0","endTime":"0","summary":"CARMEL, Ind., June 23, 2025  -- MBX Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Andreas Moraitis, M.D., as Senior Vice President of Clinical Development.\"Canvuparatide has the potential to provide a meaningful new option for people living with hypoparathyroidism, an area where patients continue to face significant unmet needs,\" said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. \"Andreas' deep expertise in endocrinology and proven track record of leading clinical development programs, from Investigational New Drug  application to New Drug Application , make him an exceptional addition to our leadership team as we advance canvuparatide and our growing pipeline of obesity and rare disease product candidates.\". MBX Biosciences is a biopharmaceutical company focused on the discov","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007","BK4099","03160","BK4604","BNTX","BK4092","HP","PBH","BK4555","BK4588","BK4585","TM"],"gpt_icon":0},{"id":"2544973148","title":"Strategic Growth and Clinical Advancements Propel MBX Biosciences to a Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2544973148","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544973148?lang=en_us&edition=fundamental","pubTime":"2025-06-18 17:55","pubTimestamp":1750240543,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Jessica Fye has maintained their bullish stance on MBX stock, giving a Buy rating on June 12. Jessica Fye’s rating is based on ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-growth-and-clinical-advancements-propel-mbx-biosciences-to-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-growth-and-clinical-advancements-propel-mbx-biosciences-to-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX"],"gpt_icon":0},{"id":"2543723636","title":"MBX Biosciences Submits IND Application for MBX 4291, Paving Way for Phase 1 Trial in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2543723636","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543723636?lang=en_us&edition=fundamental","pubTime":"2025-06-16 20:03","pubTimestamp":1750075409,"startTime":"0","endTime":"0","summary":"MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, announced on June 16, 2025, that it has submitted an Investigational New Drug  application to the U.S. Food and Drug Administration  for its novel drug, MBX 4291. This long-acting GLP-1/GIP receptor co-agonist prodrug is designed for the treatment of obesity and is expected to initiate a Phase 1 trial in the third quarter of 2025. The drug, developed using MBX's proprietary PEP platform technology, aims to provide a once-monthly injectable solution with improved tolerability and adherence. This submission marks a significant step in MBX's efforts to offer innovative treatments for endocrine and metabolic disorders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Bios","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL4BgYr6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2541852464","title":"MBX Biosciences Inc. Concluded Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541852464","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541852464?lang=en_us&edition=fundamental","pubTime":"2025-06-06 20:00","pubTimestamp":1749211210,"startTime":"0","endTime":"0","summary":"MBX Biosciences Inc. held its annual meeting of stockholders on June 5, 2025. During the meeting, stockholders voted on two proposals. The election of Tiba Aynechi, Ph.D. and P. Kent Hawryluk to the Board of Directors was approved. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL5dhBY8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2536617915","title":"MBX Biosciences to Participate in June Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2536617915","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536617915?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:00","pubTimestamp":1747742400,"startTime":"0","endTime":"0","summary":"CARMEL, Ind., May  20, 2025  (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/05/20/3084801/0/en/MBX-Biosciences-to-Participate-in-June-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4092","HP","PBH","BK4007","MBX"],"gpt_icon":0},{"id":"2536792635","title":"Buy Rating for Microbix Biosystems: Strong Antigen Revenue Growth and Mid-Term Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2536792635","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536792635?lang=en_us&edition=fundamental","pubTime":"2025-05-19 23:25","pubTimestamp":1747668310,"startTime":"0","endTime":"0","summary":"Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Microbix Biosystms (MBX – Research Report), with a price target of C$0.80. Davi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-microbix-biosystems-strong-antigen-revenue-growth-and-mid-term-market-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-microbix-biosystems-strong-antigen-revenue-growth-and-mid-term-market-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2535064747","title":"MBX Biosciences Reports Q1 2025 Financial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2535064747","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535064747?lang=en_us&edition=fundamental","pubTime":"2025-05-14 12:40","pubTimestamp":1747197656,"startTime":"0","endTime":"0","summary":"MBX Biosciences, Inc. ( ($MBX) ) has released its Q1 earnings. Here is a breakdown of the information MBX Biosciences, Inc. presented to its invest...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-reports-q1-2025-financial-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-reports-q1-2025-financial-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","LU2065732104.USD","BK4097","BK4007","PRGS"],"gpt_icon":0},{"id":"2534275352","title":"MBX Biosciences Q1 EPS $(0.71) Beats $(0.77) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2534275352","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534275352?lang=en_us&edition=fundamental","pubTime":"2025-05-12 21:32","pubTimestamp":1747056738,"startTime":"0","endTime":"0","summary":"MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.77) by 7.79 percent. This is a 93.08 percent increase over losses of $(10.26) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45347389/mbx-biosciences-q1-eps-0-71-beats-0-77-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX"],"gpt_icon":0},{"id":"2534224554","title":"Press Release: MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2534224554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534224554?lang=en_us&edition=fundamental","pubTime":"2025-05-12 20:00","pubTimestamp":1747051200,"startTime":"0","endTime":"0","summary":"Topline results for the Phase 2 Avail evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025. Investigational New Drug submission for MBX 4291 on track for 2Q 2025. $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027. \"We've followed up on our strong execution in 2024 with excellent progress on all our programs enabled by a strong balance sheet and cash position,\" said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. \"Following full enrollment of the Phase 2 Avail trial investigating canvuparatide for the treatment of hypoparathyroidism, we look forward to reporting top line results in the third quarter of 2025. We're also on track to submit our investigational new drug  application this quarter for MBX 4291, a novel glucagon-like peptide 1 /glucose-dependent insulinotropic polypeptide  co-agonist prodrug for treating obesity. In addition to these mileston","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007","BK4588","TM","BK4099","PBH","BK4092","BK4555","03160","BK4604","BK4585","HP"],"gpt_icon":0},{"id":"2533845631","title":"Microbix Biosystems to Release Q2 Fiscal 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2533845631","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533845631?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:58","pubTimestamp":1746705496,"startTime":"0","endTime":"0","summary":"Microbix Biosystms ( ($TSE:MBX) ) just unveiled an update. Microbix Biosystems Inc. has announced the release of its second quarter fiscal 2025 fin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-biosystems-to-release-q2-fiscal-2025-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-biosystems-to-release-q2-fiscal-2025-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":47,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MBX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"MBX","fiscalQuarterEnding":"2025/03","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.71},{"market":"US","date":"2025-03-17","symbol":"MBX","fiscalQuarterEnding":"2024/12","expectedEps":-0.59,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"pre","actualEps":-0.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MBX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MBX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":6,"updateTime":1752724800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MBX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MBX","date":"2025-07-29","current":-6.619813,"percent":0.438356,"low":-18.37518,"twenty":-13.762073,"median":-6.307461,"eighty":-5.075645,"high":-3.125337,"avg":-8.671385,"sd":4.42779,"marketCap":486324598},"quantilePoints":[{"date":"2024-09-13","current":-15.960592,"twenty":-13.895501,"median":-10.797864,"eighty":-10.797864,"marketCap":753339957},{"date":"2024-09-20","current":-15.949203,"twenty":-15.694582,"median":-15.111074,"eighty":-12.419885,"marketCap":752802389},{"date":"2024-09-27","current":-16.939398,"twenty":-16.33255,"median":-15.751164,"eighty":-14.917986,"marketCap":799539567},{"date":"2024-10-04","current":-16.797941,"twenty":-16.986079,"median":-16.110499,"eighty":-15.091977,"marketCap":792862827},{"date":"2024-10-11","current":-16.932325,"twenty":-16.986079,"median":-16.31699,"eighty":-15.248994,"marketCap":799205730},{"date":"2024-10-18","current":-17.024271,"twenty":-17.032759,"median":-16.518565,"eighty":-15.369232,"marketCap":803545610},{"date":"2024-10-25","current":-15.022664,"twenty":-17.021442,"median":-16.380645,"eighty":-15.369232,"marketCap":709069745},{"date":"2024-11-01","current":-15.885548,"twenty":-16.991737,"median":-16.362963,"eighty":-15.369232,"marketCap":749797857},{"date":"2024-11-08","current":-13.874718,"twenty":-16.947885,"median":-16.309917,"eighty":-15.248994,"marketCap":765593046},{"date":"2024-11-15","current":-10.66494,"twenty":-16.936569,"median":-16.143706,"eighty":-14.480386,"marketCap":588480730},{"date":"2024-11-22","current":-11.203941,"twenty":-16.918179,"median":-15.949203,"eighty":-13.805677,"marketCap":618222233},{"date":"2024-11-29","current":-12.318278,"twenty":-16.877157,"median":-15.751164,"eighty":-12.380051,"marketCap":679710282},{"date":"2024-12-06","current":-13.432616,"twenty":-16.771064,"median":-15.461179,"eighty":-11.837418,"marketCap":741198331},{"date":"2024-12-13","current":-11.470413,"twenty":-16.663558,"median":-15.31265,"eighty":-11.837418,"marketCap":632925896},{"date":"2024-12-20","current":-12.330391,"twenty":-16.662143,"median":-15.019127,"eighty":-11.803503,"marketCap":680378630},{"date":"2024-12-27","current":-12.154761,"twenty":-16.656485,"median":-14.542475,"eighty":-11.803503,"marketCap":670687579},{"date":"2025-01-03","current":-11.258446,"twenty":-16.435813,"median":-14.054537,"eighty":-11.676323,"marketCap":621229800},{"date":"2025-01-10","current":-8.290916,"twenty":-16.380645,"median":-13.850493,"eighty":-11.492215,"marketCap":457484452},{"date":"2025-01-17","current":-5.989566,"twenty":-16.372157,"median":-13.75965,"eighty":-11.117943,"marketCap":330498264},{"date":"2025-01-24","current":-6.510398,"twenty":-16.36367,"median":-13.256987,"eighty":-10.797864,"marketCap":359237243},{"date":"2025-01-31","current":-6.06224,"twenty":-16.342452,"median":-12.878476,"eighty":-9.893382,"marketCap":334508354},{"date":"2025-02-07","current":-7.473331,"twenty":-16.314161,"median":-12.457571,"eighty":-8.809325,"marketCap":412370938},{"date":"2025-02-14","current":-6.304488,"twenty":-16.290113,"median":-12.324334,"eighty":-7.444262,"marketCap":347875321},{"date":"2025-02-21","current":-6.589128,"twenty":-16.247676,"median":-12.215323,"eighty":-7.171733,"marketCap":363581507},{"date":"2025-02-28","current":-5.813937,"twenty":-16.175534,"median":-12.009413,"eighty":-6.798672,"marketCap":320807212},{"date":"2025-03-07","current":-5.989566,"twenty":-16.064646,"median":-11.803503,"eighty":-6.591551,"marketCap":330498264},{"date":"2025-03-14","current":-5.26888,"twenty":-15.958314,"median":-11.682379,"eighty":-6.514032,"marketCap":290731536},{"date":"2025-03-21","current":-4.258879,"twenty":-15.936472,"median":-11.549143,"eighty":-6.294798,"marketCap":263718287},{"date":"2025-03-28","current":-4.188707,"twenty":-15.858671,"median":-11.258446,"eighty":-6.213645,"marketCap":259373118},{"date":"2025-04-04","current":-3.260282,"twenty":-15.749749,"median":-11.107042,"eighty":-6.057395,"marketCap":201883200},{"date":"2025-04-11","current":-3.999783,"twenty":-15.687509,"median":-10.797864,"eighty":-5.922948,"marketCap":247674589},{"date":"2025-04-17","current":-4.113138,"twenty":-15.461179,"median":-10.66494,"eighty":-5.686757,"marketCap":254693707},{"date":"2025-04-25","current":-4.949799,"twenty":-15.461179,"median":-9.901861,"eighty":-5.438453,"marketCap":306501482},{"date":"2025-05-02","current":-6.477382,"twenty":-15.454106,"median":-9.653557,"eighty":-5.327647,"marketCap":401092452},{"date":"2025-05-09","current":-5.996976,"twenty":-15.31265,"median":-8.539219,"eighty":-5.438453,"marketCap":371344761},{"date":"2025-05-16","current":-5.077465,"twenty":-15.206557,"median":-7.473331,"eighty":-5.077465,"marketCap":373015980},{"date":"2025-05-23","current":-5.691675,"twenty":-15.022664,"median":-7.246225,"eighty":-5.226487,"marketCap":418138881},{"date":"2025-05-30","current":-5.787218,"twenty":-15.017006,"median":-7.134185,"eighty":-5.260401,"marketCap":425157999},{"date":"2025-06-06","current":-5.395944,"twenty":-14.885451,"median":-6.813207,"eighty":-5.315894,"marketCap":396413040},{"date":"2025-06-13","current":-4.877278,"twenty":-14.35621,"median":-6.707223,"eighty":-5.172099,"marketCap":358309257},{"date":"2025-06-20","current":-4.677092,"twenty":-14.130289,"median":-6.595185,"eighty":-5.059804,"marketCap":343602533},{"date":"2025-06-27","current":-5.136611,"twenty":-14.052953,"median":-6.564904,"eighty":-5.017962,"marketCap":377361148},{"date":"2025-07-03","current":-5.673476,"twenty":-13.977856,"median":-6.515167,"eighty":-5.013234,"marketCap":416801906},{"date":"2025-07-11","current":-5.641628,"twenty":-13.855338,"median":-6.4303,"eighty":-5.035235,"marketCap":414462200},{"date":"2025-07-18","current":-5.548359,"twenty":-13.804466,"median":-6.320845,"eighty":-5.055522,"marketCap":407610204},{"date":"2025-07-25","current":-5.928259,"twenty":-13.766918,"median":-6.298431,"eighty":-5.072006,"marketCap":435519554},{"date":"2025-07-29","current":-6.619813,"twenty":-13.762073,"median":-6.307461,"eighty":-5.075645,"marketCap":486324598}],"updateTime":1753889395608}}}